Skip to main content
NewslettersWatchlist

Hls Therapeutics Inc(HLS-T)
TSX

Today's Change
Real-Time Last Update
Day Low3.13
Day High3.26
Open:3.13
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment Conference
Newswire.ca
HLS Therapeutics Announces Q2 2024 Financial Results
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference Call
AI-generated - The Globe and Mail
HLS Therapeutics: Top 10 Undervalued Drug Manufacturers Industry Stocks (HLS)
Newswire.ca
HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust
AI-generated - The Globe and Mail
HLS Therapeutics: Top 10 Undervalued Drug Manufacturers Industry Stocks (HLS)
Newswire.ca
HLS Therapeutics Reports Annual Meeting Results
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment
Newswire.ca
HLS Therapeutics Announces Q1 2024 Financial Results
Newswire.ca
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Newswire.ca
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Newswire.ca
HLS Therapeutics Announces Fiscal 2023 Financial Results
Newswire.ca
HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call
Newswire.ca
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
Newswire.ca
HLS Therapeutics Announces CFO Departure

Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.